• Explore /
  • Poster
  • / OReO/ENGOT Ov-38 trial: Impact of maintenance olaparib rechallenge according to ovarian cancer patient prognosis—An exploratory joint analysis of the BRCA and non-BRCA cohorts.

OReO/ENGOT Ov-38 trial: Impact of maintenance olaparib rechallenge according to ovarian cancer patient prognosis—An exploratory joint analysis of the BRCA and non-BRCA cohorts.

Abstract Poster

Authors

null

Frederic Selle

GINECO & Groupe Hospitalier Diaconesses Croix Saint Simon, Paris, France

Frederic Selle , Bernard Asselain , François Montestruc , Fernando Bazan , Beatriz Pardo , Vanda Salutari , Frederik Marmé , Anja Ør Knudsen , Alessandra Bologna , Radoslaw Madry , Rosalind Glasspool , Stéphanie Henry , Jacob Korach , Stephanie Lheureux , Bob Shaw , Ana Santaballa , Raffaella Cioffi , Ulrich Canzler , Alain Lortholary , Eric Pujade-Lauraine

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Clinical Trial Registration Number

NCT03106987

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 5558)

DOI

10.1200/JCO.2022.40.16_suppl.5558

Abstract #

5558

Poster Bd #

437

Abstract Disclosures

Similar Posters

First Author: Brian Dougherty

First Author: Philipp Harter

First Author: Angelina Tjokrowidjaja

First Author: Ursula Matulonis